Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease

Research output: Contribution to journalArticle

13 Scopus citations


Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalAnnals of Clinical and Laboratory Science
Issue number2
StatePublished - Jan 1 1989

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this